<?xml version="1.0" encoding="UTF-8"?>
<p>Overall, 39 patients with MPN, including 7 patients with essential thrombocythemia (ET) (18%), 21 with polycythemia vera (PV) (54%), and 11 with myelofibrosis (MF) [28%; of whom 5 were primary myelofibrosis (PMF), 3 post-ET MF and 3 post-PV MF] have been accrued in 10 institutions across Switzerland between May 2015 and February 2016. The patients fulfilled the 2008 World Health Organization (WHO) diagnostic criteria for MPN.
 <sup>
  <xref rid="b10-1040710" ref-type="bibr">10</xref>
 </sup> All patients were 
 <italic>JAK2</italic>-V617F-positive with a mutant allele burden at study entry more than 20% in granulocyte DNA. The trial was planned and conducted in accordance with the Declaration of Helsinki, the Guidelines for Good Clinical Practice (GCP) issued by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and the requirements of the respective national regulatory authorities. The local ethics committees of all participating centers have given approval to the trial and written informed consent was obtained from all patients prior to enrollment. Details of the inclusion and exclusion criteria are specified in the 
 <italic>Online Supplementary Appendix</italic>.
</p>
